WED-152 Design and study population of MITIGATE: the first multinational randomized controlled clinical trial in IgG4 related disease, evaluating the efficacy and safety of the CD19 B cell depleting agent inebilizumab

Autor: Stone, John, Culver, Emma, Khosroshahi, Arezou, Zhang, Wen, Torre, Emanuel Della, Okazaki, Kazuichi, Tanaka, Yoshiya, Lohr, Matthias, Schleinitz, Nicolas, Dong, Lingli, Umehara, Hisanori, Lanzillotta, Marco, Wallace, Zachary, Ebbo, Mikael, Webster, George, Wu, Yanping, Cimbora, Daniel, Rampal, Nishi
Zdroj: In Journal of Hepatology June 2024 80 Supplement 1:S710-S710
Databáze: ScienceDirect
Externí odkaz: